SPRINT® PNS System Now Covered Nationally by Aetna®

Aetna's updated medical policy recognizes SPRINT PNS as a covered treatment option for certain patients with intractable neuropathic pain.

Mar. 13, 2026 at 2:48pm

Got story updates? Submit your updates here. ›

SPR Therapeutics, a leading medical device company, announced that Aetna has updated its medical policy to designate the SPRINT PNS System as a covered treatment option for patients with intractable neuropathic pain when Aetna's selection criteria are met. This decision expands access to the SPRINT PNS System for an estimated 22.3 million covered lives across the United States.

Why it matters

The SPRINT PNS System is a non-opioid, minimally invasive pain treatment option that provides durable pain relief without a permanent implant. Aetna's coverage decision aligns with evidence-based guidelines and increases access to this therapy, which can benefit millions of patients suffering from chronic pain.

The details

Under Aetna's updated medical policy, the SPRINT PNS System is now considered a covered treatment option for appropriate patients who meet the policy's criteria. The policy recognizes SPRINT PNS as a standalone device intended to provide durable pain relief without a permanent implant and notes that it does not require a trial prior to use given its 60-day treatment duration. The updated policy includes additional covered indications such as chronic pain syndrome, polyneuropathy, intractable neuropathic pain, chronic pain due to trauma, and other chronic pain.

  • Aetna published the updated medical policy on March 13, 2026.

The players

SPR Therapeutics

A privately held medical device company focused on improving the lives of people living with pain by providing a non-opioid, minimally invasive pain treatment option.

Aetna

A leading health insurance company that has updated its medical policy to designate the SPRINT PNS System as a covered treatment option for certain patients with intractable neuropathic pain.

Dr. Usman Latif

A Board-Certified Anesthesiologist and Pain Management physician, SPR consultant, and lead author of the recent American Society of Pain and Neuroscience (ASPN) published evidence-based consensus guidelines for the use of peripheral nerve stimulation.

Maria Bennett

The President, CEO, and Founder of SPR Therapeutics.

Got photos? Submit your photos here. ›

What they’re saying

“This policy expansion is a pivotal step forward to align national coverage with evidence-based guidelines and a game changer for millions of patients who could benefit from peripheral nerve stimulation.”

— Dr. Usman Latif, Board-Certified Anesthesiologist and Pain Management physician, SPR consultant, and lead author of the recent American Society of Pain and Neuroscience (ASPN) published evidence-based consensus guidelines for the use of peripheral nerve stimulation

“Aetna's recognition of the significant clinical data and successful outcomes delivered via SPRINT PNS in thousands of real-world patients* is encouraging and offers millions of members a better chance to find relief.”

— Maria Bennett, President, CEO, and Founder of SPR

The takeaway

Aetna's coverage decision for the SPRINT PNS System represents a significant step forward in providing patients with a non-opioid, minimally invasive pain treatment option that can offer durable pain relief without the need for a permanent implant. This expansion of access to peripheral nerve stimulation aligns with evidence-based guidelines and can benefit millions of individuals suffering from chronic pain.